The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score

BACKGROUND: Breast cancer (BC) remains the leading cause of cancer‐related deaths worldwide. High recurrence risk Luminal BC receives adjuvant chemotherapy in addition to standard hormone therapy. Considering the heterogeneity of Luminal B BC, a more accurate classification model is urgently needed....

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zheng‐Jun, Liu, Yu‐Xiao, Huang, Yue, Chen, Zu‐Jin, Zhang, Hao‐Zhi, Yu, Yue, Wang, Xin, Cao, Xu‐Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939104/
https://www.ncbi.nlm.nih.gov/pubmed/35909232
http://dx.doi.org/10.1002/cam4.5089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939104/
https://www.ncbi.nlm.nih.gov/pubmed/35909232
http://dx.doi.org/10.1002/cam4.5089

Ejemplares similares